Literature DB >> 15520276

Increased gene dosage of Ink4a/Arf results in cancer resistance and normal aging.

Ander Matheu1, Cristina Pantoja, Alejo Efeyan, Luis M Criado, Juan Martín-Caballero, Juana M Flores, Peter Klatt, Manuel Serrano.   

Abstract

Mammalian genes frequently present allelic variants that differ in their expression levels and that, in the case of tumor suppressor genes, can be of relevance for cancer susceptibility and aging. We report here the characterization of a novel mouse model with increased activity for the Ink4a and Arf tumor suppressors. We have generated a "super Ink4a/Arf" mouse strain carrying a transgenic copy of the entire Ink4a/Arf locus. Cells derived from super Ink4a/Arf mice have increased resistance to in vitro immortalization and oncogenic transformation. Importantly, super Ink4a/Arf mice manifest higher resistance to cancer compared to normal, nontransgenic, mice. Finally, super Ink4a/Arf mice have normal aging and lifespan. Together, these results indicate that modest increases in the activity of the Ink4a/Arf tumor suppressor result in a beneficial cancer-resistant phenotype without affecting normal viability or aging.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15520276      PMCID: PMC528894          DOI: 10.1101/gad.310304

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  38 in total

Review 1.  Putting the stress on senescence.

Authors:  M Serrano; M A Blasco
Journal:  Curr Opin Cell Biol       Date:  2001-12       Impact factor: 8.382

2.  Induction of senescence by oncogenic Ras.

Authors:  I Palmero; M Serrano
Journal:  Methods Enzymol       Date:  2001       Impact factor: 1.600

3.  Putative telomere-independent mechanisms of replicative aging reflect inadequate growth conditions.

Authors:  R D Ramirez; C P Morales; B S Herbert; J M Rohde; C Passons; J W Shay; W E Wright
Journal:  Genes Dev       Date:  2001-02-15       Impact factor: 11.361

4.  Small changes in expression affect predisposition to tumorigenesis.

Authors:  Hai Yan; Zuzana Dobbie; Stephen B Gruber; Sanford Markowitz; Kathy Romans; Francis M Giardiello; Kenneth W Kinzler; Bert Vogelstein
Journal:  Nat Genet       Date:  2001-12-17       Impact factor: 38.330

5.  Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras.

Authors:  C Pantoja; M Serrano
Journal:  Oncogene       Date:  1999-09-02       Impact factor: 9.867

6.  p53 mutant mice that display early ageing-associated phenotypes.

Authors:  Stuart D Tyner; Sundaresan Venkatachalam; Jene Choi; Stephen Jones; Nader Ghebranious; Herbert Igelmann; Xiongbin Lu; Gabrielle Soron; Benjamin Cooper; Cory Brayton; Sang Hee Park; Timothy Thompson; Gerard Karsenty; Allan Bradley; Lawrence A Donehower
Journal:  Nature       Date:  2002-01-03       Impact factor: 49.962

7.  Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis.

Authors:  N E Sharpless; N Bardeesy; K H Lee; D Carrasco; D H Castrillon; A J Aguirre; E A Wu; J W Horner; R A DePinho
Journal:  Nature       Date:  2001-09-06       Impact factor: 49.962

8.  Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis.

Authors:  E Latres; M Malumbres; R Sotillo; J Martín; S Ortega; J Martín-Caballero; J M Flores; C Cordón-Cardo; M Barbacid
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 9.  Cancer as a complex genetic trait: tumor susceptibility in humans and mouse models.

Authors:  Allan Balmain
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

10.  Invasive melanoma in Cdk4-targeted mice.

Authors:  R Sotillo; J F García; S Ortega; J Martin; P Dubus; M Barbacid; M Malumbres
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

View more
  58 in total

1.  Stem cell therapeutics--reality versus hype and hope.

Authors:  Nicolas H Zech; Karl-Heinz Preisegger; Peter Hollands
Journal:  J Assist Reprod Genet       Date:  2010-12-08       Impact factor: 3.412

2.  Making the case for private cord blood banking: mission accomplished!: comment to Schmidt et al., Stem Cell Rev and Rep (2010) 6:234-236.

Authors:  Peter Hollands; Karl-Heinz Preisegger
Journal:  Stem Cell Rev Rep       Date:  2011-09       Impact factor: 5.739

3.  Antiviral action of the tumor suppressor ARF.

Authors:  María A García; Manuel Collado; César Muñoz-Fontela; Ander Matheu; Laura Marcos-Villar; Javier Arroyo; Mariano Esteban; Manuel Serrano; Carmen Rivas
Journal:  EMBO J       Date:  2006-09-07       Impact factor: 11.598

Review 4.  Senescence regulation by the p53 protein family.

Authors:  Yingjuan Qian; Xinbin Chen
Journal:  Methods Mol Biol       Date:  2013

5.  Increased p53 activity does not accelerate telomere-driven ageing.

Authors:  Isabel García-Cao; Marta García-Cao; Antonia Tomás-Loba; Juan Martín-Caballero; Juana M Flores; Peter Klatt; María A Blasco; Manuel Serrano
Journal:  EMBO Rep       Date:  2006-03-31       Impact factor: 8.807

6.  mTORC1 and p53: clash of the gods?

Authors:  Paul Hasty; Zelton Dave Sharp; Tyler J Curiel; Judith Campisi
Journal:  Cell Cycle       Date:  2013-01-01       Impact factor: 4.534

Review 7.  p53--a Jack of all trades but master of none.

Authors:  Melissa R Junttila; Gerard I Evan
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

8.  Significance of cellular senescence in aging and cancer.

Authors:  Angela Grimes; Sathees B C Chandra
Journal:  Cancer Res Treat       Date:  2009-12-31       Impact factor: 4.679

9.  Aging and cancer resistance in lymphoid progenitors are linked processes conferred by p16Ink4a and Arf.

Authors:  Robert A J Signer; Encarnacion Montecino-Rodriguez; Owen N Witte; Kenneth Dorshkind
Journal:  Genes Dev       Date:  2008-11-15       Impact factor: 11.361

10.  Limited role of murine ATM in oncogene-induced senescence and p53-dependent tumor suppression.

Authors:  Alejo Efeyan; Matilde Murga; Barbara Martinez-Pastor; Ana Ortega-Molina; Rebeca Soria; Manuel Collado; Oscar Fernandez-Capetillo; Manuel Serrano
Journal:  PLoS One       Date:  2009-05-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.